deepCDR has developed proprietary machine learning technology that enables significantly faster development of antibody therapies. Using deep sequencing and genome editing methods that published in elite scientific journals, we provide rapid discovery and optimization of antibody drugs.

deepCDR was acquired by Alloy Therapeutics.


Mattenstrasse 26, 4058 Basel, Switzerland

Facts & figures
  • Type of organization
    Private company
  • Year of foundation
  • Number of employees in Switzerland